Atumelnant

Atumelnant
Clinical data
Other names	CRN04894
Identifiers
	IUPAC name N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-ethoxyphenyl)-3-[(2R)-2-ethyl-4-[1-(trifluoromethyl)cyclobutanecarbonyl]piperazin-1-yl]pyridine-2-carboxamide;
CAS Number	2392970-97-5;
PubChem CID	146361282;
IUPHAR/BPS	13339;
UNII	NR57FH6U1N;
Chemical and physical data
Formula	C33H42F3N5O3
Molar mass	613.726 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@@H]1CN(CCN1C2=C(N=C(C=C2)C3=CC=CC=C3OCC)C(=O)N[C@@H]4CN5CCC4CC5)C(=O)C6(CCC6)C(F)(F)F;
	InChI InChI=InChI=1S/C33H42F3N5O3/c1-3-23-20-40(31(43)32(14-7-15-32)33(34,35)36)18-19-41(23)27-11-10-25(24-8-5-6-9-28(24)44-4-2)37-29(27)30(42)38-26-21-39-16-12-22(26)13-17-39/h5-6,8-11,22-23,26H,3-4,7,12-21H2,1-2H3,(H,38,42)/t23-,26-/m1/s1; Key:QJRFBKYETDVAJQ-ZEQKJWHPSA-N;

Atumelnant (CRN04894) is an investigational new drug developed by Crinetics Pharmaceuticals for the treatment of adrenocorticotropic hormone (ACTH)-dependent endocrine disorders. It is a selective antagonist of the melanocortin type 2 receptor (MC2R), also known as the ACTH receptor, which is primarily expressed in the adrenal glands.^[1] Atumelnant is being evaluated to treat conditions such as congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome caused for example by pituitary adenomas.^[2]

References

^ "Atumelnant (CRN04894)". crinetics.com. 14 August 2020.
^ Varlamov EV, Gheorghiu ML, Fleseriu M (December 2024). "Pharmacological management of pituitary adenomas - what is new on the horizon?". Expert Opinion on Pharmacotherapy. doi:10.1080/14656566.2024.2446625. PMID 39718553.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.